bioAffinity Technologies (BIAF) Registration filing summary
Event summary combining transcript, slides, and related documents.
Registration filing summary
16 Jun, 2026Offering details and pricing
Registered securities include common stock and pre-funded warrants, with shares and warrants to be sold directly to investors through a placement agent on a best-efforts basis.
Purchase price per share and per pre-funded warrant is set, with pre-funded warrants exercisable at $0.007 per share.
Placement Agent receives a 7.5% cash fee on gross proceeds and 3% of shares sold as warrants.
The offering is subject to market conditions and may be closed in one or more tranches.
No guarantee of successful placement; the company retains the right to accept or reject offers.
Underwriters and syndicate
WallachBeth Capital LLC acts as exclusive placement agent, with the ability to retain sub-agents or selected dealers.
Placement Agent is not obligated to underwrite or purchase securities for its own account.
Placement Agent receives expense reimbursement up to $120,000.
Placement Agent Warrants are subject to transfer restrictions for 180 days post-offering.
Risk factors and disclosures
The company provides indemnification to the Placement Agent for liabilities except in cases of negligence or willful misconduct.
No conflicts of interest with FINRA members are disclosed; compliance with FINRA rules is affirmed.
The company is not required to register as an investment company after the offering.
Latest events from bioAffinity Technologies
- Noninvasive lung cancer diagnostic sees growth, but ongoing capital needs and risks remain.BIAF
Registration filing12 Jun 2026 - CyPath Lung enables precise, non-invasive risk stratification for pulmonary nodules, improving care.BIAF
Status update14 May 2026 - CyPath® Lung revenue surged, but losses widened and liquidity concerns remain.BIAF
Q1 202611 May 2026 - AI-powered lung diagnostics firm registers 497,483 shares for resale; proceeds depend on warrant exercises.BIAF
Registration filing30 Apr 2026 - AI-powered CyPath Lung enables accurate, noninvasive early lung cancer detection and market growth.BIAF
Investor presentation8 Apr 2026 - Proxy seeks approval for director elections, equity plan changes, and a reverse stock split.BIAF
Proxy Filing16 Mar 2026 - CyPath® Lung test sales surged 99% in 2025, driving record revenue and future growth momentum.BIAF
Q4 202513 Mar 2026 - Ten key proposals, including equity plan expansion and reverse stock split, recommended for approval.BIAF
Proxy Filing5 Mar 2026 - High-accuracy lung cancer test expands nationwide with VA access and FDA trial plans.BIAF
Maxim Group’s 2024 Healthcare Virtual Summit19 Jan 2026